The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RVMD | +24.92% | +83.05% | +12.85% | +101% |
| S&P | +18.37% | +110.18% | +16.02% | +104% |
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$3.80M | -35.9% |
| Gross Margin | -285.18% | 0.0% |
| Market Cap | $6.85B | 7.0% |
| Market Cap / Employee | $9.79M | 0.0% |
| Employees | 700 | 0.0% |
| Net Income | -$247.79M | -86.0% |
| EBITDA | -$260.91M | -69.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $402.44M | 46.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $119.70M | 51.4% |
| Short Term Debt | $13.09M | 57.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -38.32% | -2.3% |
| Return On Invested Capital | -26.24% | 1.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$229.21M | -75.5% |
| Operating Free Cash Flow | -$221.76M | -73.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 4.86 | 4.68 | 2.90 | 3.30 | -11.10% |
| Price to Sales | 349.67 | 1162.77 | 8637.68 | 10197.27 | - |
| Price to Tangible Book Value | 5.09 | 4.91 | 3.00 | 3.41 | -11.81% |
| Enterprise Value to EBITDA | -35.31 | -25.58 | -19.76 | -18.91 | -40.70% |
| Return on Equity | -47.2% | -29.3% | -36.7% | -46.6% | 14.45% |
| Total Debt | $86.71M | $135.84M | $134.34M | $132.79M | 51.91% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
